AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Bamco Inc. NY

Bamco Inc. NY reduced its position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 19.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 107,652 shares of the company's stock after selling 25,592 shares during the period. Bamco Inc. NY's holdings in AstraZeneca were worth $7,053,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Banque Transatlantique SA acquired a new position in AstraZeneca during the 4th quarter worth approximately $26,000. Albion Financial Group UT increased its position in AstraZeneca by 68.9% during the 4th quarter. Albion Financial Group UT now owns 608 shares of the company's stock worth $40,000 after purchasing an additional 248 shares in the last quarter. Versant Capital Management Inc raised its holdings in shares of AstraZeneca by 2,618.5% in the 4th quarter. Versant Capital Management Inc now owns 734 shares of the company's stock worth $48,000 after purchasing an additional 707 shares during the period. Crews Bank & Trust purchased a new stake in shares of AstraZeneca during the 4th quarter valued at about $55,000. Finally, Golden State Wealth Management LLC purchased a new position in AstraZeneca in the 4th quarter worth approximately $55,000. Institutional investors and hedge funds own 20.35% of the company's stock.

Wall Street Analyst Weigh In

AZN has been the subject of a number of analyst reports. Morgan Stanley began coverage on AstraZeneca in a report on Wednesday, February 12th. They issued an "overweight" rating for the company. BNP Paribas began coverage on AstraZeneca in a research note on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target for the company. Finally, UBS Group raised AstraZeneca from a "neutral" rating to a "buy" rating in a research note on Thursday, February 13th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, AstraZeneca has an average rating of "Buy" and a consensus target price of $88.00.

AstraZeneca Stock Up 0.4 %

AstraZeneca stock traded up $0.27 during midday trading on Friday, reaching $67.57. The stock had a trading volume of 6,215,921 shares, compared to its average volume of 5,141,616. The company has a fifty day moving average price of $71.33 and a two-hundred day moving average price of $69.70. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $87.68. The company has a market capitalization of $209.55 billion, a P/E ratio of 29.90, a PEG ratio of 1.42 and a beta of 0.40.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.14. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The company had revenue of $13.59 billion for the quarter, compared to analysts' expectations of $13.71 billion. During the same period last year, the firm earned $2.06 earnings per share. AstraZeneca's quarterly revenue was up 7.2% on a year-over-year basis. As a group, equities analysts expect that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.